This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:AB-CHMINACA: Difference between revisions
>LockPicker m merged redundant references |
>LockPicker panels |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}} | |||
{{headerpanel|{{Approval}}}} | |||
{{SummarySheet}} | {{SummarySheet}} | ||
{{Talk:SubstanceBox/AB-CHMINACA}} | {{Talk:SubstanceBox/AB-CHMINACA}} | ||
| Line 12: | Line 14: | ||
==Pharmacology== | ==Pharmacology== | ||
{{pharmacology}} | |||
AB-CHMINACA is a selective CB1 receptor agonist, being approximately 30 times more active at CB1 over CB2. The reported EC<sub>50</sub> values are 7.4 ± 1.5nM at CB1 and 232.4 ± 231.2nM at CB2.<ref>Wiley JL, Marusich JA, Lefever TW, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol–Like Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics. 2015;354(3):328-339. doi:10.1124/jpet.115.225326. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538877/</ref> | AB-CHMINACA is a selective CB1 receptor agonist, being approximately 30 times more active at CB1 over CB2. The reported EC<sub>50</sub> values are 7.4 ± 1.5nM at CB1 and 232.4 ± 231.2nM at CB2.<ref>Wiley JL, Marusich JA, Lefever TW, et al. AB-CHMINACA, AB-PINACA, and FUBIMINA: Affinity and Potency of Novel Synthetic Cannabinoids in Producing Δ9-Tetrahydrocannabinol–Like Effects in Mice. The Journal of Pharmacology and Experimental Therapeutics. 2015;354(3):328-339. doi:10.1124/jpet.115.225326. | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538877/</ref> | ||
| Line 56: | Line 59: | ||
}} | }} | ||
}} | }} | ||
===Experience reports=== | ===Experience reports=== | ||
There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | There are currently no anecdotal reports which describe the effects of this compound within our [[experience index]]. Additional experience reports can be found here: | ||
| Line 84: | Line 88: | ||
*'''United Kingdom''': AB-CHMINACA is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016. It is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | *'''United Kingdom''': AB-CHMINACA is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016. It is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | ||
*'''United States''': In January 2015, AB-CHMINACA was designated as a Schedule I controlled substance in the United States.<ref>Federal Register Vol. 80 No. 20, Friday January 30, 2015. "Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I" (GPO.gov) | https://www.gpo.gov/fdsys/pkg/FR-2015-01-30/pdf/2015-01776.pdf</ref> | *'''United States''': In January 2015, AB-CHMINACA was designated as a Schedule I controlled substance in the United States.<ref>Federal Register Vol. 80 No. 20, Friday January 30, 2015. "Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cannabinoids Into Schedule I" (GPO.gov) | https://www.gpo.gov/fdsys/pkg/FR-2015-01-30/pdf/2015-01776.pdf</ref> | ||
==See also== | ==See also== | ||
| Line 92: | Line 95: | ||
*[[AB-FUBINACA]] | *[[AB-FUBINACA]] | ||
*[[THJ-018]] | *[[THJ-018]] | ||
==External links== | ==External links== | ||
*[https://en.wikipedia.org/wiki/AB-CHMINACA AB-CHMINACA (Wikipedia)] | *[https://en.wikipedia.org/wiki/AB-CHMINACA AB-CHMINACA (Wikipedia)] | ||
| Line 98: | Line 102: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category: | [[Category:Articles in talk page]] | ||
[[Category: | [[Category:Research chemical]] | ||
[[Category: | [[Category:Indazolecarboxamide]] | ||
[[Category:Cannabinoid]] | [[Category:Cannabinoid]] | ||